

William E Fantegrossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2377394/publications.pdf>

Version: 2024-02-01

96
papers

3,389
citations

147566

31
h-index

143772

57
g-index

97
all docs

97
docs citations

97
times ranked

2963
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. <i>Toxicological Sciences</i> , 2022, 187, 175-185.	1.4	4
2	Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109468.	1.6	2
3	Major Metabolites of the Synthetic Cannabinoid 5F-ADB Retain High Affinity and Full Efficacy at CB1 Receptors; Potential Mechanism Contributing to Enhanced Toxicity?. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
4	Effects of Laboratory Housing Conditions on Core Temperature and Locomotor Activity in Mice. <i>Journal of the American Association for Laboratory Animal Science</i> , 2021, 60, 272-280.	0.6	1
5	Locomotor effects of 3,4-methylenedioxyamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. <i>Psychopharmacology</i> , 2020, 237, 431-442.	1.5	5
6	Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. <i>Molecules</i> , 2020, 25, 4820.	1.7	2
7	Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 195, 172949.	1.3	15
8	The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 16-23.	1.3	7
9	Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine. <i>Psychopharmacology</i> , 2020, 237, 2613-2620.	1.5	3
10	The synthetic cathinone 3,4-methylenedioxypropylvalerone increases impulsive action in rats. <i>Behavioural Pharmacology</i> , 2020, 31, 309-321.	0.8	3
11	In vivo effects of 3,4-methylenedioxyamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107850.	1.6	3
12	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid (adamantan-1-yl)-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00561.	1.3	1
13	Effects of Ambient Temperature and Social Housing on Locomotor Activity, Thermoregulation, and Weight Loss Following Binge-Administration of Structurally Related Abused Psychostimulants. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
14	In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 9-17.	1.3	17
15	Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ⁹ -Tetrahydrocannabinol and JWH-018. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 259-269.	1.3	4
16	Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). <i>Xenobiotica</i> , 2019, 49, 1388-1395.	0.5	3
17	Repeated administration of synthetic cathinone 3,4-methylenedioxypropylvalerone persistently increases impulsive choice in rats. <i>Behavioural Pharmacology</i> , 2019, 30, 555-565.	0.8	7
18	Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 146-156.	1.3	21

#	ARTICLE	IF	CITATIONS
19	Acquisition of Oral Ethanol Self-administration in Long-Evans Rats: Model Validation for Treatment of Alcohol Use Disorders. <i>FASEB Journal</i> , 2019, 33, 499.4.	0.2	0
20	Acute Administration of 3,4-Methylenedioxypropylamphetamine (MDPV) Increases Motor Impulsivity in Rats. <i>FASEB Journal</i> , 2019, 33, 805.10.	0.2	0
21	Introduction to special issue: Therapeutic and abuse-related effects of cannabis and cannabinoids.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 299-300.	1.3	1
22	Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. <i>Drug Metabolism Reviews</i> , 2018, 50, 65-73.	1.5	47
23	Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 597-602.	1.0	24
24	Cocaine-Responsive miRNA and Blood Pressure Elevation. <i>Hypertension</i> , 2018, 71, 561-562.	1.3	2
25	Phencyclidine-like in vivo effects of methoxetamine in mice and rats. <i>Neuropharmacology</i> , 2018, 134, 158-166.	2.0	9
26	Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypropylamphetamine (MDPV)-elicited hyperthermia and locomotor stimulation in mice. <i>Neuropharmacology</i> , 2018, 134, 13-21.	2.0	12
27	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to ¹¹ C-THC. <i>Frontiers in Pharmacology</i> , 2018, 9, 1084.	1.6	20
28	Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. <i>Drug and Alcohol Dependence</i> , 2018, 192, 285-293.	1.6	6
29	Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00403.	1.1	4
30	Pharmacological Characterization of Synthetic Cannabinoid MAM-2201: Radioligand Binding and Abuse-Related Effects. <i>FASEB Journal</i> , 2018, 32, 825.2.	0.2	0
31	Predicting Impulsivity and Compulsivity in Mice Using a Rapid Drug Abuse Liability Battery (RDALB) Assessing Hyperneophagia, Locomotor Reactivity, and Novelty Preference. <i>FASEB Journal</i> , 2018, 32, 551.7.	0.2	0
32	In vitro and In vivo Effects of Phase 1 Hydroxylated Metabolites of the Synthetic Cannabinoid AB-PINACA [(S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide]. <i>FASEB Journal</i> , 2018, 32, 825.1.	0.2	0
33	Synthetic Pot: Not Your Grandfather's Marijuana. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 257-276.	4.0	78
34	Discriminative Stimulus Effects of Psychostimulants. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 39, 29-49.	0.8	3
35	Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development. <i>Pharmacological Research</i> , 2017, 125, 161-177.	3.1	32
36	Effects of orally self-administered bath salt constituent 3,4-methylenedioxypropylamphetamine (MDPV) in mice. <i>Drug and Alcohol Dependence</i> , 2017, 179, 408-415.	1.6	14

#	ARTICLE	IF	CITATIONS
37	Monoaminergic toxicity induced by cathinone phthalimide: An in vitro study. <i>Neuroscience Letters</i> , 2017, 655, 76-81.	1.0	8
38	In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. <i>PLoS ONE</i> , 2016, 11, e0150602.	1.1	28
39	Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 249-262.	0.8	86
40	Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypropylamphetamine (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells. <i>Neuroscience Letters</i> , 2016, 629, 125-130.	1.0	33
41	Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypropylamphetamine in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 615-623.	1.3	68
42	3,4-methylenedioxypropylamphetamine (MDPV) Induces Cytotoxic Effects on Human Dopaminergic SH-SY5Y Cells. <i>Journal of Drug and Alcohol Research</i> , 2016, 5, 1-6.	0.9	11
43	Cocaine-Like Discriminative Stimulus Effects of Mephedrone and Naphyrone in Mice. <i>Journal of Drug and Alcohol Research</i> , 2016, 5, 1-5.	0.9	16
44	Repeated administration of phytocannabinoid δ^9 -THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. <i>Pharmacological Research</i> , 2015, 102, 22-32.	3.1	43
45	Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT _{2A} receptors, in mice. <i>Psychopharmacology</i> , 2015, 232, 1039-1047.	1.5	45
46	Effects of 3,4-methylenedioxypropylamphetamine (MDPV) and 3,4-methylenedioxymethamphetamine (MDMA) on Place Conditioning in Mice. <i>FASEB Journal</i> , 2015, 29, 930.9.	0.2	0
47	Effects of Synthetic Cannabinoid JWH-018 and Phytocannabinoid δ^9 -THC on Learning and Memory in Mice. <i>FASEB Journal</i> , 2015, 29, 615.5.	0.2	0
48	Emerging Designer Drugs. , 2014, , 575-596.		3
49	Tolerance and Cross-Tolerance to Head Twitch Behavior Elicited by Phenethylamine- and Tryptamine-Derived Hallucinogens in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 485-491.	1.3	22
50	δ^9 -THC exposure attenuates aversive effects and reveals appetitive effects of K2/Spice™ constituent JWH-018 in mice. <i>Behavioural Pharmacology</i> , 2014, 25, 253-257.	0.8	21
51	Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. <i>Current Addiction Reports</i> , 2014, 1, 129-136.	1.6	95
52	Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to δ^9 -THC: Mechanism underlying greater toxicity?. <i>Life Sciences</i> , 2014, 97, 45-54.	2.0	236
53	Baths Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines. <i>Journal of Neuroscience</i> , 2014, 34, 15150-15158.	1.7	133
54	Predisposing effects of neonatal visceral pain on abuse-related effects of morphine in adult male Sprague Dawley rats. <i>Psychopharmacology</i> , 2014, 231, 4281-4289.	1.5	7

#	ARTICLE	IF	CITATIONS
55	Psychostimulant Abuse and HIV Infection: Cocaine, Methamphetamine, and "Bath Salts"™ Cathinone Analogs. <i>Current Addiction Reports</i> , 2014, 1, 237-242.	1.6	11
56	In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ^9 -THC in mice: Inhalation versus intraperitoneal injection. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 40-47.	1.3	81
57	Functional consequences of synthetic cannabinoid metabolites and CYP2C9 polymorphisms (838.4). <i>FASEB Journal</i> , 2014, 28, 838.4.	0.2	0
58	Targeted Metabolomic Approach for Assessing Human Synthetic Cannabinoid Exposure and Pharmacology. <i>Analytical Chemistry</i> , 2013, 85, 9390-9399.	3.2	31
59	Forensic investigation of K2, Spice, and "bath salt" commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. <i>Forensic Science International</i> , 2013, 233, 416-422.	1.3	92
60	Differential Drug-Drug Interactions of the Synthetic Cannabinoids JWH-018 and JWH-073: Implications for Drug Abuse Liability and Pain Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 350-361.	1.3	50
61	Not simply synthetic tetrahydrocannabinol. <i>Journal of Pediatrics</i> , 2013, 163, 1797-1798.	0.9	2
62	Novel technology for modulating locomotor activity as an operant response in the mouse: Implications for neuroscience studies involving "exercise" in rodents. <i>Journal of Neuroscience Methods</i> , 2013, 212, 338-343.	1.3	6
63	Design, Synthesis, and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4537-4550.	2.9	39
64	In vivo Effects of Abused "Bath Salt"™ Constituent 3,4-methylenedioxypyrovalerone (MDPV) in Mice: Drug Discrimination, Thermoregulation, and Locomotor Activity. <i>Neuropsychopharmacology</i> , 2013, 38, 563-573.	2.8	136
65	Discriminative stimulus effects of emerging arylcyclohexylamine drugs of abuse in rats. <i>FASEB Journal</i> , 2013, 27, 658.8.	0.2	0
66	Tolerance and cross-tolerance among high-efficacy synthetic cannabinoids JWH-018 and JWH-073 and low-efficacy phytocannabinoid Δ^9 -THC. <i>FASEB Journal</i> , 2013, 27, 1097.1.	0.2	1
67	Effects of neonatal visceral pain on morphine tolerance, dependence, and withdrawal in rats. <i>FASEB Journal</i> , 2013, 27, 886.11.	0.2	0
68	AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. <i>Neuropharmacology</i> , 2012, 63, 905-915.	2.0	84
69	Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. <i>Biochemical Pharmacology</i> , 2012, 83, 952-961.	2.0	143
70	Conditioned taste aversion elicited by synthetic cannabinoid JWH-018 in mice is attenuated by pretreatment with phytocannabinoid Δ^9 -THC. <i>FASEB Journal</i> , 2012, 26, 660.4.	0.2	1
71	In vivo effects of "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: contribution of ambient temperature and monoamines. <i>FASEB Journal</i> , 2012, 26, 661.7.	0.2	0
72	Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine. <i>Analytical Chemistry</i> , 2011, 83, 4228-4236.	3.2	138

#	ARTICLE	IF	CITATIONS
73	Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. <i>PLoS ONE</i> , 2011, 6, e21917.	1.1	192
74	Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. <i>Psychopharmacology</i> , 2010, 210, 75-83.	1.5	15
75	Interaction of 5-HT _{2A} and 5-HT _{2C} Receptors in <i>R</i> -2,5-Dimethoxy-4-iodoamphetamine-Elicited Head Twitch Behavior in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 728-734.	1.3	89
76	Wheel running behavior and thermoregulation in mice: effects of MDMA and methamphetamine. <i>FASEB Journal</i> , 2010, 24, 766.8.	0.2	0
77	Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine and Its Enantiomers in Mice: Pharmacokinetic Considerations. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 1006-1015.	1.3	22
78	Escalation of food-maintained responding and sensitivity to the locomotor stimulant effects of cocaine in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 67-74.	1.3	29
79	Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. <i>Psychopharmacology</i> , 2009, 205, 337-347.	1.5	17
80	Endocrine and neurochemical effects of S(+) and R(-)-MDMA in rhesus macaques. <i>FASEB Journal</i> , 2009, 23, 589.11.	0.2	0
81	Discriminative stimulus effects of MDMA and its enantiomers in mice: pharmacokinetic considerations. <i>FASEB Journal</i> , 2009, 23, 743.2.	0.2	0
82	The behavioral pharmacology of hallucinogens. <i>Biochemical Pharmacology</i> , 2008, 75, 17-33.	2.0	195
83	Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT _{1A} and 5-HT _{2A} receptors in rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 88, 358-365.	1.3	62
84	A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. <i>Neuroscience</i> , 2008, 151, 533-543.	1.1	91
85	In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 1-12.	1.3	26
86	Discriminative stimulus effects of hallucinogens and psychostimulants in S(+)-MDMA, and R(-)-MDMA trained mice. <i>FASEB Journal</i> , 2008, 22, 713.2.	0.2	0
87	MDMA use and neurocognition: a meta-analytic review. <i>Psychopharmacology</i> , 2007, 189, 531-537.	1.5	111
88	Effects of the hallucinogen DPT on operant behavior in mice. <i>FASEB Journal</i> , 2007, 21, A780.	0.2	0
89	The hallucinogen-like effects of N,N-dipropyltryptamine are mediated by 5-HT _{1A} and 5-HT _{2A} receptors in the mouse. <i>FASEB Journal</i> , 2007, 21, A780.	0.2	0
90	Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?. <i>Psychopharmacology</i> , 2006, 189, 471-482.	1.5	18

#	ARTICLE	IF	CITATIONS
91	Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. <i>Behavioural Pharmacology</i> , 2005, 16, 627-633.	0.8	61
92	Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. <i>Psychopharmacology</i> , 2005, 181, 529-536.	1.5	23
93	Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. <i>Psychopharmacology</i> , 2005, 181, 496-503.	1.5	63
94	Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2004, 29, 1270-1281.	2.8	120
95	Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. <i>Psychopharmacology</i> , 2003, 166, 202-211.	1.5	111
96	3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. <i>Psychopharmacology</i> , 2002, 161, 356-364.	1.5	121